Pediatrics Clinical Trials
Leukemia/Lymphoma clinical trials
2022-0312: Phase II study of pedi-cRIB: mini-hyper-CVD with condensed rituximab, inotuzumab ozogamicin and blinatumomab (cRIB) for relapsed therapy for pediatric with B-Cell lineage acute lymphocytic leukemia
2021-0547: A Phase II Study to Evaluate Safety and Efficacy of CB-103 in Combination with Venetoclax in Adolescent and Young Adult Patients with Relapsed/Refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL)
2020-0996 or COGAAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP) in a Phase II trial.
2021-0983 or COGANHL1931: A Randomized Phase III trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
2022-0804 or COGAPAL2020SC: Pediatric Acute Leukemia (PedAL) screening trial - developing new therapies for relapsed leukemias.
2023-0369: A Phase II Children's Oncology Group (COG) study of tovorafenib (DAY101) in relapsed and refractory Langerhans cell histiocytosis.
2019-0997: A Phase I/II clinical trial examines the menin inhibitor SNDX-5613, a targeted therapy for relapsed/refractory leukemias with the mixed lineage leukemia (MLL)/KMT2A gene rearrangement or the nucleophosmin 1 (NPM1) mutation
2021-0121: A Phase I, multicenter, open-label, dose escalation study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered FHD-286 in subjects with advanced hematologic malignancies.
2021-0877: A Phase I/II open-label, first-in-human, dose-escalation study of SAR443579 administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplasia (HR-MDS).
2021-0916: A Phase II study of the combination of azacitidine and pembrolizumab for patients relapsed/refractory Hodgkin's lymphoma.
2022-0347: Phase Ib study evaluating the safety and efficacy of autologous CD30.CAR-T in combination with programmed cell death protein-1 checkpoint inhibitor (Nivolumab) in relapsed or refractory classical Hodgkin lymphoma patients after failure of frontline therapy (ACTION).
COGAALL1731: A Phase III Trial Investigating blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
2016-0211: Lead in and Phase II study of Clofarabine, Etoposide, Cyclophosphamide (CEC), Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in relapsed/refractory acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL).
2016-0772: Phase I study of palbociclib in combination with various agents in patients with relapsed/refractory leukemias.
2020-0686: A Phase II study to determine the response kinetics, safety and efficacy of brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin and prednisone for patients with untreated primary mediastinal large b-cell. Also known as the PACIFIC Trial.
2020-0484: A Phase I study of liposomal cytarabine and daunorubicin (CPX‐351) in combination with Gemtuzumab Ozogamicin (GO) in relapsed/refractory pediatric patients with acute myeloid leukemia (AML).
2021-0061: A study to evaluate the usability, adherence, and diagnostic performance of a novel system to non-invasively detect severe neutropenia.
2021-0181: A multicenter Phase II study of belantamab mafodotin in relapsed or refractory plasmablastic lymphoma and anaplastic lymphoma kinase (ALK)+ large b-cell lymphoma.
2021-0815: A Phase I first-in-human dose-escalation and dose-expansion study of BMF-219, an oral irreversible menin inhibitor, in adult patients with acute leukemia including those with an MLL/KMT2A gene rearrangement or NPM1 mutation.
2021-0482: A multicenter, open-label, Phase II study to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric patients with solid tumors or lymphomas and treated with myelosuppressive chemotherapy.
2015-0313: A Phase II study of personalized natural killer (NK) cell immunotherapy in Cord Blood Transplantation.
COGAALL1631: International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones
SWOGS1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (open through Lymphoma Department)
2014-0845: Phase II clinical trial with HCVAD+Blinatumomab+Inotuzumab for B-ALL
COGAALL1732: A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
2020-0818 or COGAAML1831: Phase III Randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin (GO) to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
AAML1921 or 2020-0448: A Phase I/II study of bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ chronic myeloid leukemia (CML).
2016-0316: A Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia and Non-Hodgkin lymphoma (ZUMA-4)
2021-1059: A Phase I/II study investigating the all oral combination of the menin inhibitor SNDX-5613 with decitabine/cedazuridine (ASTX727) and venetoclax in Acute Myeloid Leukemia (SAVE-ML).
2018-1092: Bispecific NK Engager (AFM13) combined with cord blood-derived NK cells for refractory Hodgkin and other CD30+ lymphomas
2017-0937: Cardioprotection with Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS), Myeloid Blast Phase of Chronic Myeloid Leukemia (CML), Ph+ AML, and Myeloid Blast Phase of Myeloproliferative Neoplasms
2019-0997: A Phase I/II, Open-label, Dose-Escalation and Dose-Expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemia including those harboring an MLL/KMT2A gene rearrangement or nucleophosmin 1 (NPM1) mutation
2019-1142: A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors (GO40871)
2018-1061: Multiple part clinical trial of brentuximab vedotin in classical Hodgkin lymphoma
2019-0318: Phase II front-line PET/CT response adapted brentuximab vedotin and nivolumab incorporated and radiation-free management of early stage classical Hodgkin lymphoma
2020-0460: Phase 2 multi-center study evaluating safety and efficacy of CD30-directed genetically modified autologous T-cells in adult and pediatric patients with relapsed CD30+ classical Hodgkin lymphoma
2021-0620: Muscle vibration for vincristine associated neuropathy
Neuro-oncology/CNS clinical trials
2018-0524: A Phase I dose-finding, safety study of oral AMXT 1501 dicaprate and Difluoromethylornithine (DFMO) in patients with advanced solid tumors
2023-0163: A Phase Ib trial of eribulin in combination with Irinotecan and temozolamide in children with relapsed or refractory solid tumors
2022-0043: 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy administered to pediatric patients with high-risk neuroblastoma. It is a multi-center, dose-escalation, open-label, non-randomized, Phase I/IIa theranostic clinical trial
2019-1097 or COGANCS1831: A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG).
2020-0220 or COGACNS1833: A Phase III Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1).
2021-0716 or COGACNS2021: A Phase II Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.
2018-0524: Phase I dose-finding, safety study of oral AMXT 1501 dicaprate and difluoromethylornithine (DFMO) in patients with advanced solid tumors.
2020-0495: A pilot study of Allogeneic Hematopoietic Cell Transplantation for patients with patients with high-grade Central Nervous System Malignancies
COGACNS1831: A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
COGACNS1721:- A Phase II Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600 Mutation
COGACNS1833: A Phase III Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Non-neural solid tumor clinical trials
2021-0390 or AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
2021-0934 or ARST2031: A Randomized Phase III Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC)Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO for the treatment of patients with high risk rhabdomyosarcoma (RMS).
2020-0992 or ADVL2021: Eli Lilly CAMPFIRE—a Randomized, Open-Label Phase I/II Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.
2022-0256 or AOST2031: A Phase III Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
2022-0573 or ARST2032: A Prospective Phase III Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma.
2023-0468 or ARET2121: Intravitreal Melphalan for Intraocular Retinoblastoma. This Phase II trial tests the safety and side effects of adding melphalan to standard chemotherapy in the early treatment of patients with retinoblastoma (RB).
2020-1280: Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.
2020-0793: Phase II evolutionary inspired therapy for newly diagnosed, metastatic, fusion positive rhabdomyosarcoma.
2020-0439: Phase II study of avapritinib in patients with CKIT or PDGFRA mutation-positive malignant solid tumors.
2021-0888: A Phase I, multicenter, open-label, dose-escalation and expansion study of intravenously administered 23ME-00610 in patients with advanced solid malignancies
2021-0873: A Phase II multi-center open-label basket trial of ABI-009 (nab sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in tuberous sclerosis complex (1 or 2) genes.
2014-0913: A Phase I dose-escalating study of two drugs—MM-398 (Irinotecan Sucrosofate Liposome Injection) and intravenous cyclophosphamide in recurrent or refractory pediatric solid tumors.
2019-0405: A Phase II single arm open-label clinical trial of ADP-A2M4 SPEAR T cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma
2021-0093: Phase I/II dose escalation and dose expansion study of ZN-c3 in combination with gemcitabine in adult and pediatric patients with relapsed or refractory osteosarcoma
2020-1340: Phase I Study of Safety, PK, PD and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study – CCNE1 altered)
ARST1921 or 2020-1195: A safety, pharmacokinetic and efficacy study of a secretase inhibitor, nirogacestat (PF-03084014; IND#146375) in children and adolescents with progressive, surgically unresectable desmoid tumors.
COGARST1431 A Randomized Phase III Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
COGAPEC1621 Pediatric MATCH (Molecular Analysis for Therapy Choice)
COGAREN1721 A Randomized Phase II Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
COGAHEP1531 An Intergroup Study by Société Internationale d’Oncologie Pédiatrique (SIOPEL) in collaboration with COG and the Japanese Children’s Cancer Group (JCCG). Coordinating Center: Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
COGAGCT1531 A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
2017-0530: Phase I Trial of the LSD1 Inhibitor SP-2577 in Patients with Relapsed or Refractory Ewing Sarcoma
2019-1048: A Phase I/II , Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations
2020-0496: A pilot study of allogeneic hematopoietic stem cell transplantation for patients with high-risk solid tumors
2020-0160: Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
2018-0643: Phase II study of Nivolumab with Ipilimumab in solid tumors of high mutational burden
2015-0158: PLX8394 in patients with advanced, unresectable solid tumors
2017-1064: A Phase I/II Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced SolidTumors
2020-0155: ARRAY-162-115: A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
2020-0159: A Phase II multi-arm study to test the efficacy of Oleclumab and Durvalumab in multiple sarcoma subtypes
2019-1142: A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors (GO40871)
2020-0833: A Phase I/II open-label multicenter study to assess the safety, tolerability , pharmacokinetics, pharmacodynamics and efficacy of PC14586 in patients with advanced solid tumors harboring a p53 Y220C mutation
2020-0150: A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
Phase I studies/investigational cancer therapeutics
2011-0953: A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors.
2017-0567: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known to be a target of an FDA-approved anti-cancer drug or to predict sensitivity to an FDA-approved anti-cancer drug.
Sarcoma and solid tumor clinical trials
2022-0709: A Phase I/II, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and efficacy of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors followed by expansion to assess efficacy and safety in pediatric and young adult participants with relapsed/refractory Ewing sarcoma.
2021-0409: A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults with Recurrent/metastatic Osteosarcoma (TACOS)
2021-0443: Phase I/II study of CAR.70- engineered IL15-transduced cord blood-derived NK cells in conjunction with lymphodepleting chemotherapy for the management of advanced solid tumors
2021-0619: A first-in-human phase 1 trial of T-Cell membrane-anchored tumor targeted Il12 (Attil12)- T-Cell therapy in subjects with advanced/metastatic soft tissue and bone sarcoma
2018-0224: A Phase I/II study of gemcitabine and docetaxel in combination with hydroxychloroquine (Autophagy Inhibitor) in patients with recurrent osteosarcoma.
2018-0643: A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H).
2017-0085: Ex-vivo expanded allogeneic NK cells for the treatment of solid tumors of pediatric origin in Children and Young Adults.
COGAGCT1531: A Phase III Study of active surveillance for low risk and a randomized trial of carboplatin versus cisplatin for standard risk pediatric and adult patients with germ cell tumors.
2017-0672: Clinical study to assess efficacy and safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types).
2015-0720: Phase I study of Aerosol Gemcitabine in patients with Solid Tumors and Pulmonary Metastases.
2014-0692: Phase I trial of dasatinib, cyclophosphamide and temsirolimus for advanced pediatric solid tumors and central nervous system (CNS) tumors.
2016-0023: Phase I, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma.
Stem cell and cell therapy trials for pediatric/adult patients
2020-0523: A Phase I/II, double-blind, placebo-controlled, dose escalation and expansion study of ALVR106 in addition to standard of care for the treatment of high-risk patients with respiratory viral infections after hematopoietic cell transplant
2021-0712: A Phase II hematopoietic cell transplantation using treosulfan-based conditioning for the treatment of bone marrow failure diseases
2019-0405: A Phase II single arm open-label clinical trial of ADP-A2M4 SPEAR T cells in subjects with advanced synovial sarcoma or myxoid/round cell liposarcoma.
2016-0316: A Phase I/II Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)
2019-0481: Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
2020-0171: BMT CTN PROTOCOL 1507: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
2018-0855: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
2020-0496: A pilot study of allogeneic hematopoieticstem cell transplantation for patients with high-risk solid tumors
2018-0664: Adoptive Cord Blood Immunotherapy using expanded cord blood T-cells for EBV, CMV, BKV and Adenovirus reactivation/infection or prophylaxis (CHEERS)
2020-0495: A pilot study of Allogeneic Hematopoietic Cell Transplantation for patients with patients with high-grade Central Nervous System Malignancies
2020-0952: PTIS: Pre-transplant immunosuppression and related haploidentical hematopoietic cell transplantation for patients with severe hemoglobinopathies
2019-1122: Randomized controlled pilot study of two doses of cord blood tissue-derived mesenchymal stromal cells combined with ruxolitinib versus ruxolitinib alone for steroid-refractory aGVHD.
2017-1003: Open label dose escalation and dose expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART22 (Allo Anti-CD22 CAR) in patients with relapsed or refractory CD22+ B-ALL
2020-0375: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
2017-0771: Multicenter, Open Label, Phase 3 trial of ATA129 for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study).
2013-1018: A Phase I study of CD19+ CAR (chimeric antigen receptor) T cells for patients with advanced Lymphoid Malignancies.
2015-0313: A Phase II study of personalized natural killer (NK) cell immunotherapy in Cord Blood Transplantation.
2014-0279: Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by ex vivo Expansion in Patients with BK Virus Infection and JC Virus Infection
2016-0137: Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation
2018-0964: A Phase II Pilot Trial To Estimate Survival After A Non-Total Body Irradiation (TBI) Based Conditioning Regimen In Patients Diagnosed With B-Acute Lymphoblastic Leukemia (ALL) Who Are Pre-Allogeneic Hematopoietic Cell Transplantation (HCT) Next-Generation-Sequence (NGS) Minimal Residual Disease (MRD) Negative (PBMTC ONC1701).
2018-0840: Newly Diagnosed Children (Less Than 10 Years Old) with Medulloblastoma and Other Central Nervous System Embryonal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Either Single Cycle (Low Risk Patients) or Randomization (High Risk Patients) to Either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue.
2012-0506: Phase I/II study of Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
2019-0353: A Phase II Study of Venetoclax in Combination with Azacitidine in the Post-Transplant Setting for High-Risk Acute Leukemia Patients.
2016-0641: A Phase I/II Study of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction with Lymphodepleting Chemotherapy in Patients with Relapsed/Refractory B-Lymphoid Malignancies.
2018-0744: Managed Access Program (MAP) to Provide Access to CTL019, for Acute Lymphoblastic Leukemia (ALL) or Diffuse Large b-cell Lymphoma (DLBCL) Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification For Commercial Release (Treatment Plan CCTL019B2003I).
2019-0079: Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There are No Appropriate Alternative Therapies.
2013-0657: A Phase II Most Closely HLA Matched Allogeneic CMV Specific Cytotoxic T-Lymphocytes (CTL) to Treat CMV Infection after Hematopoietic Stem Cell Transplantation (HSCT).
2017-0350: Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Adenovirus Specific T Cells for Therapy of Adenovirus Related Disease in Immunocompromised Patients.
2018-0221: A Phase I/II Study of Anti-viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation.
2020-0138: A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRαβ+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC “CSIDE” Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801
Endocrine clinical trials
2017-0202: A Phase I oral LOXO-292 advanced solid tumors, including RET-fusion non-small cell lung cancer and medullary thyroid cancer, and other tumors with increased RET activity.
2017-0418: Phase I/II study of TRK inhibitor LOXO-195 with NTRK fusion (previously treated) or non-fusion NTRK altered cancers.
Observational, wellness/psychosocial and biobanking (non-therapeutic) studies:
COG-ALTE07C1: Study of the neuropsychological, social, emotional, and behavioral outcomes in children with cancer.
COGAPEC14B1: The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
COGALTE16C1: Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
Registry trials for pediatric patients
PA13-0014: Circulating tumor cells in pediatric cancer patients as predictors of chemotherapy response and metastatic disease.
2014-0938: This protocol seeks to gather biospecimens over a period of years for all tumor types. During the clinical research study, samples of normal and tumor tissue, as well as blood, bone, marrow, and bodily fluid will be collected over time. This is part of the Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) Moon Shot™ Platform at MD Anderson.
Branko Cuglievan, M.D., assistant professor and section chief for Pediatric Leukemia and Lymphoma, greets a clinical trial patient before starting an exam.
In 2023, U.S. News and World Report ranked the Children's Cancer Hospital among the Top 20 Best Hospitals for Pediatric Cancer. The designation highlights our commitment to multiple aspects of care, including providing access to novel clinical trials which have the potential to advance the field.